Results 181 to 190 of about 151,900 (300)

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

The Significance of Somatic Variants Involved in the Development of Pancreatic Cancer in Patients with HBOC-Associated Germline Variants. [PDF]

Genes (Basel)
Uchiyama K, Nishikubo H, Sano T, Furukawa Y, Ma D, Imanishi D, Ishidate T, Gao H, Fan C, Yashiro M.   +9 more
europepmc   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Clinical and genomic characterization of KRAS G13X non-small cell lung carcinoma. [PDF]

Front Oncol
Staum BJ, Lakra R, Ravindra A, Mott SL, Ma D, Zeitler W, Byrne M, Choradia N, Naqash AR, Aljumaily R, Furqan M.   +10 more
europepmc   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors. [PDF]

Sci Adv
Hu L, Ahmari N, Schaeper A, Pundavela J, Kim MO, Dombi E, Wu J, Brunmair J, Petronczki ÖY, Ratner N.   +9 more
europepmc   +1 more source

Immune‐Related Prognostic Gene Identification in Lung Squamous Cell Carcinoma With the Cancer Genome Atlas Mining and Immunohistochemistry Validation

iNew Medicine, EarlyView.
ABSTRACT Objective In the cancer microenvironment, stromal and immune cells hold clinical importance. In lung squamous cell carcinoma (LSCC), the aim of this study was to find immune‐linked gene expression that has prognostic pertinence. Methods From the Cancer Genome Atlas, this study obtained the LSCC gene expression profile.
Weijia Jiang, Jing Xu, Wenwen Ma, Qingjie Zhu, Pawin Pongkorpsakol, Guoping Sun   +5 more
wiley   +1 more source

KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones. [PDF]

Cancer Res
Tomaschko M, Ng K, Moore C, Pillsbury CE, Rana S, Campbell J, Mukherjee S, Mikolajczak A, Anastasiou P, de Castro A, Alonso de la Vega A, de Carné Trécesson S, Goehring NW, Molina-Arcas M, Downward J.   +14 more
europepmc   +1 more source

The Case for the KRA [PDF]

, 2021
openaire   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source